Physician profile
Meiting Liang
NPI 1396094587
$25,103.43
in general payments reported to CMS, 2019-2025
22 companies · $5,310 in 2025
The $5,310 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,902 · 2022: $4,827 · 2023: $6,112 · 2024: $4,951 · 2025: $5,310.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,075 · Food and Beverage: $7,027 · Travel and Lodging: $172 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,075.00 |
| Food and Beverage | $7,027.47 |
| Travel and Lodging | $172.00 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,520.31 | 2021-2025 | |
| Gilead Sciences, INC. | $2,627.15 | 2021-2025 | Livdelzi, Vemlidy, Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,296.70 | 2021-2025 | Xifaxan, Trulance |
| Janssen Biotech, INC. | $593.81 | 2022-2025 | Tremfya, Stelara |
| Madrigal Pharmaceuticals | $488.35 | 2024-2025 | Rezdiffra, Resmetirom |
| Nestle Healthcare Nutrition INC. | $292.77 | 2021-2023 | |
| Intra-Sana Laboratories | $233.40 | 2022-2023 | Reltone 200 Mg, Glycate, Reltone 400 Mg |
| Pfizer INC. | $184.66 | 2022-2025 | |
| Ardelyx, INC. | $160.14 | 2022-2024 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $135.71 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $123.38 | 2024-2025 | Zenpep |
| Ibsa Pharma INC. | $116.67 | 2022 | |
| Braintree Laboratories, INC. | $78.96 | 2021-2024 | Suflave, Sutab |
| Celgene Corporation | $50.83 | 2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $42.18 | 2024-2025 | Voquezna |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vivus LLC | $36.72 | 2021 | |
| Redhill Biopharma INC. | $34.55 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $19.48 | 2024 | |
| Exact Sciences Corporation | $18.77 | 2023 | Cologuard Collection Kit |
| Qol Medical, LLC | $16.97 | 2023 | Sucraid |
| W. L. Gore & Associates, INC. | $16.39 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.53 | 2023 | Gattex |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meiting Liang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.